These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens. Bornot A; Blackett C; Engkvist O; Murray C; Bendtsen C J Biomol Screen; 2014 Jun; 19(5):696-706. PubMed ID: 24441646 [TBL] [Abstract][Full Text] [Related]
7. Open access high throughput drug discovery in the public domain: a Mount Everest in the making. Roy A; McDonald PR; Sittampalam S; Chaguturu R Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896 [TBL] [Abstract][Full Text] [Related]
8. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Meanwell NA Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149 [TBL] [Abstract][Full Text] [Related]
9. Phenotypic screens targeting neurodegenerative diseases. Zhang M; Luo G; Zhou Y; Wang S; Zhong Z J Biomol Screen; 2014 Jan; 19(1):1-16. PubMed ID: 23958650 [TBL] [Abstract][Full Text] [Related]
11. Impact of selection bias on the evaluation of clusters of chemical compounds in the drug discovery process. Alonso A; Milanzi E; Molenberghs G; Buyck C; Bijnens L Pharm Stat; 2015; 14(2):129-38. PubMed ID: 25420717 [TBL] [Abstract][Full Text] [Related]
12. Identification of drug candidates and repurposing opportunities through compound-target interaction networks. Cichonska A; Rousu J; Aittokallio T Expert Opin Drug Discov; 2015 Dec; 10(12):1333-45. PubMed ID: 26429153 [TBL] [Abstract][Full Text] [Related]
13. Enrichment analysis for discovering biological associations in phenotypic screens. Polyakov VR; Moorcroft ND; Drawid A J Chem Inf Model; 2014 Feb; 54(2):377-86. PubMed ID: 24437550 [TBL] [Abstract][Full Text] [Related]
14. Challenges of antibacterial discovery revisited. Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956 [TBL] [Abstract][Full Text] [Related]
15. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity. Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667 [TBL] [Abstract][Full Text] [Related]
16. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads. Bergsdorf C; Ottl J Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747 [TBL] [Abstract][Full Text] [Related]
17. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience. Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652 [TBL] [Abstract][Full Text] [Related]
18. Cell and small animal models for phenotypic drug discovery. Szabo M; Svensson Akusjärvi S; Saxena A; Liu J; Chandrasekar G; Kitambi SS Drug Des Devel Ther; 2017; 11():1957-1967. PubMed ID: 28721015 [TBL] [Abstract][Full Text] [Related]
19. [The discovery process in the pharmaceutical industry]. Scatton B J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071 [TBL] [Abstract][Full Text] [Related]